Back to Search
Start Over
Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma
- Source :
- Alonso-Álvarez, S, Manni, M, Montoto, S, Sarkozy, C, Morschhauser, F, Wondergem, M J, Guarini, A, Magnano, L, Alcoceba, M, Chamuleau, M, Galimberti, S, Gomes da Silva, M, Holte, H, Zucca, E, Lockmer, S, Aurer, I, Marcheselli, L, Stepanishyna, Y, Caballero Barrigón, M D, Salles, G & Federico, M 2021, ' Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma ', European Journal of Cancer, vol. 157, pp. 132-139 . https://doi.org/10.1016/j.ejca.2021.08.005, European Journal of Cancer, 157, 132-139. Pergamon
- Publication Year :
- 2021
-
Abstract
- Background: Primary refractory (PREF) follicular lymphoma (FL) has a completely different clinical course from that of FL that responds to front-line treatments. In addition to having poor responses to salvage therapies, it seems that patients with PREF are at increased risk of histological transformation (HT). The Aristotle consortium presented the opportunity of investigating the risk of HT in a very large series of cases. Thus, we investigated the risk of HT in patients with PREF FL compared with that of responding patients or in stable disease and ultimately their outcome. Methods: Six thousand three hundred thirty-nine patients from the Aristotle database were included in the analysis. These patients had a histologically confirmed grade 1, 2 or 3a FL diagnosed between 1997 and 2013. The primary end-points were the cumulative incidence (CI) of HT at the first progression or relapse and the survival after transformation. Findings.: The 5-year CI of HT among patients with PREF was 34% (95% confidence interval (CI): 27–43), whilst it was 7.1% (95% CI: 6.0–8.5) in the group of patients with partial response (PR) or stable disease (SD) (PR + SD) and 3.5% (95% CI: 3.0–4.2) in the group of patients achieving complete response (CR). The 5-year survival after relapse (SAR) was 33% (95% CI: 28–39) for the PREF group, 57% (95% CI 54–61) in patients with PR, 51% (95% CI 43–58) in the SD group after first-line therapy and 63% (95% CI: 66–72) in patients with CR after initial treatment (p-value
- Subjects :
- Male
Cancer Research
medicine.medical_specialty
Lymphoma, B-Cell
Lymphoma
Rituximab era
Follicular lymphoma
Primary refractory follicular lymphoma
Cell Transformation
Gastroenterology
Stable Disease
Refractory
primary refractory follicular lymphoma
histologic transformation
rituximab era
Internal medicine
medicine
80 and over
Histologic transformation
Aged
Aged, 80 and over
Cell Transformation, Neoplastic
Female
Humans
Lymphoma, Follicular
Middle Aged
Retrospective Studies
In patient
Cumulative incidence
B-cell lymphoma
Neoplastic
business.industry
B-Cell
Follicular
medicine.disease
Confidence interval
Oncology
Refractory Follicular Lymphoma
business
Subjects
Details
- Language :
- English
- ISSN :
- 09598049
- Database :
- OpenAIRE
- Journal :
- Alonso-Álvarez, S, Manni, M, Montoto, S, Sarkozy, C, Morschhauser, F, Wondergem, M J, Guarini, A, Magnano, L, Alcoceba, M, Chamuleau, M, Galimberti, S, Gomes da Silva, M, Holte, H, Zucca, E, Lockmer, S, Aurer, I, Marcheselli, L, Stepanishyna, Y, Caballero Barrigón, M D, Salles, G & Federico, M 2021, ' Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma ', European Journal of Cancer, vol. 157, pp. 132-139 . https://doi.org/10.1016/j.ejca.2021.08.005, European Journal of Cancer, 157, 132-139. Pergamon
- Accession number :
- edsair.doi.dedup.....a667e202072aae0de08517a7589f6531
- Full Text :
- https://doi.org/10.1016/j.ejca.2021.08.005